X0206 3 2019-05-08 0 0001662774 Cortexyme, Inc. CRTX 0001771657 Takeda Ventures, Inc. 435 TASSO STREET, SUITE 300 PALO ALTO CA 94301 0 0 1 0 0001395064 TAKEDA PHARMACEUTICAL CO LTD 1-1, NIHONBASHI-HONCHO 2-CHOME CHUO-KU TOKYO M0 103-8668 JAPAN 0 0 1 0 0001688140 Takeda Pharmaceuticals International AG THURGAUERSTRASSE 130 8152 GLATTPARK-OPFIKON ZURICH 2M GERMANY 0 0 1 0 0001716229 Takeda Pharmaceuticals U.S.A., Inc. ONE TAKEDA PARKWAY DEERFIELD IL 60015 0 0 1 0 Common Stock 0 D Series A Reedemable Convertible Preferred Stock Common Stock 2360071 D Series B Reedemable Convertible Preferred Stock Common Stock 319731 D The Series A Redeemable Convertible Preferred Stock is convertible into the issuer's common stock on a one-for-one basis and has no expiration date. It will automatically convert into common stock upon the closing of the issuer's initial public offering. These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited. The Series B Redeemable Convertible Preferred Stock is convertible into the issuer's common stock on a one-for-one basis and has no expiration date. It will automatically convert into common stock upon the closing of the issuer's initial public offering. Exhibit 24.1: Power of Attorney - Takeda Ventures, Inc. Exhibit 24.2: Power of Attorney - Takeda Pharmaceutical Company Limited Exhibit 24.3: Power of Attorney - Takeda Pharmaceuticals International AG Exhibit 24.4: Power of Attorney - Takeda Pharmaceuticals U.S.A., Inc. /s/ Christopher Lowe, as Attorney-in-Fact for Takeda Ventures, Inc. 2019-05-08 /s/ Christopher Lowe, as Attorney-in-Fact for Takeda Pharmaceutical Company Limited 2019-05-08 /s/ Christopher Lowe, as Attorney-in-Fact for Takeda Pharmaceuticals International AG 2019-05-08 /s/ Christopher Lowe, as Attorney-in-Fact for Takeda Pharmaceuticals U.S.A, Inc. 2019-05-08